Back to Stakeholders

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

Public Payer / National Coverage Authority

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 8, 2026

Focus Areas

HTA Evidence AppraisalCost-Effectiveness ModelingCoverage Policy DesignFormulary & Access Criteria

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessLong-Term SafetyPatient-Reported OutcomesReal-World Evidence

Market Access Notes

G-BA publishes formal benefit-assessment resolutions that directly shape German reimbursement access; esketamine has an AMNOG evaluation and English resolution materials.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Primary Access Link

Public Sector Governance Snapshot

Health Technology Assessment Agencies

Authority Type

Health Technology Assessment Agency

Jurisdiction

National

Coverage

1 country

Framework Status

Active

Function Areas

HTA Evidence AppraisalClinical Guidance PublicationHealth System Implementation

Governance Notes

Wave 5 L3 completion pass for Federal Joint Committee (G-BA).

Verification

Verified

Psychedelic Engagement

Psychedelic-Adjacent Focus

Last Verified

Apr 16, 2026

Verification Notes

Official HTA decision body with direct esketamine (Spravato) appraisal materials.

Primary Governance Link

Policy Instruments

Esketamine (Spravato) HTA dossier review

HTA Recommendation / Decision

G-BA esketamine dossier module

Quick Facts

Website
Visit